NASDAQ:RGEN

Repligen News Headlines

$191.52
+1.52 (+0.80 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$189.60
$192.97
50-Day Range
$165.87
$220.95
52-Week Range
$109.38
$228.84
Volume248,623 shs
Average Volume404,779 shs
Market Capitalization$10.52 billion
P/E Ratio132.08
Dividend YieldN/A
Beta0.83

Repligen (NASDAQ RGEN) News Headlines Today

SourceHeadline
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa - NasdaqGilead (GILD) Gets FDA Nod for Label Expansion of Epclusa - Nasdaq
nasdaq.com - June 11 at 5:39 PM
Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi - NasdaqBristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi - Nasdaq
nasdaq.com - June 11 at 5:39 PM
Vertex (VRTX) Ends Further Study on AAT Deficiency Candidate - NasdaqVertex (VRTX) Ends Further Study on AAT Deficiency Candidate - Nasdaq
nasdaq.com - June 11 at 12:39 PM
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor - NasdaqOmeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor - Nasdaq
nasdaq.com - June 10 at 5:47 PM
Arenas (ARNA) Etrasimod Gets FDAs Orphan Drug Tag for EoE - NasdaqArena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE - Nasdaq
nasdaq.com - June 10 at 12:47 PM
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel - NasdaqArena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel - Nasdaq
nasdaq.com - June 9 at 2:56 PM
VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status - NasdaqVBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status - Nasdaq
nasdaq.com - June 9 at 2:56 PM
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold - Nasdaqbluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold - Nasdaq
nasdaq.com - June 8 at 5:26 PM
Alexions (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids - NasdaqAlexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids - Nasdaq
nasdaq.com - June 8 at 5:26 PM
If You Had Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Youd Have Earned 717% Returns - Yahoo FinanceIf You Had Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago You'd Have Earned 717% Returns - Yahoo Finance
finance.yahoo.com - June 8 at 12:25 PM
If You Had Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Youd Have Earned 717% ReturnsIf You Had Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago You'd Have Earned 717% Returns
finance.yahoo.com - June 8 at 12:25 PM
Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound? - NasdaqRepligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound? - Nasdaq
nasdaq.com - June 5 at 7:26 PM
Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound? - Yahoo FinanceRepligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
finance.yahoo.com - June 3 at 3:19 PM
Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound?Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - June 3 at 3:19 PM
Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma - NasdaqBristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma - Nasdaq
nasdaq.com - June 3 at 10:18 AM
J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection - NasdaqJ&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection - Nasdaq
nasdaq.com - June 2 at 12:32 PM
Repligen (NASDAQ:RGEN) Stock Price Down 4.8%Repligen (NASDAQ:RGEN) Stock Price Down 4.8%
americanbankingnews.com - June 1 at 2:20 PM
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients - NasdaqOmeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients - Nasdaq
nasdaq.com - May 31 at 6:38 PM
Why Rambus Inc. (NASDAQ:RMBS) Could Be Worth Watching - NasdaqWhy Rambus Inc. (NASDAQ:RMBS) Could Be Worth Watching - Nasdaq
nasdaq.com - May 31 at 6:38 PM
Omeros (OMER) Announces Data on Narsoplimab in COVID-19 PatientsOmeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients
finance.yahoo.com - May 31 at 6:38 PM
Repligen Corporation to Present at Upcoming Investor Conferences - Yahoo FinanceRepligen Corporation to Present at Upcoming Investor Conferences - Yahoo Finance
finance.yahoo.com - May 25 at 8:09 AM
Repligen Corporation to Present at Upcoming Investor ConferencesRepligen Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - May 25 at 8:09 AM
Bristol Myers (BMY) Opdivo-Yervoy Combo Gets Positive CHMP OpinionBristol Myers' (BMY) Opdivo-Yervoy Combo Gets Positive CHMP Opinion
finance.yahoo.com - May 24 at 5:54 PM
Heres Why Entera Bio (ENTX) Stock Has Almost Tripled This Year - NasdaqHere's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year - Nasdaq
nasdaq.com - May 19 at 1:01 PM
Regeneron (REGN) Resumes Enrollment in Lymphoma CohortsRegeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
finance.yahoo.com - May 18 at 7:34 PM
Lillys (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC - NasdaqLilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC - Nasdaq
nasdaq.com - May 18 at 2:34 PM
Repligen (NASDAQ:RGEN) Updates FY 2021 Earnings GuidanceRepligen (NASDAQ:RGEN) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 18 at 2:08 PM
Insider Selling: Repligen Co. (NASDAQ:RGEN) CFO Sells 470 Shares of StockInsider Selling: Repligen Co. (NASDAQ:RGEN) CFO Sells 470 Shares of Stock
americanbankingnews.com - May 18 at 9:40 AM
Repligen Co. (NASDAQ:RGEN) VP Ralf Kuriyel Sells 710 SharesRepligen Co. (NASDAQ:RGEN) VP Ralf Kuriyel Sells 710 Shares
americanbankingnews.com - May 18 at 9:40 AM
Form 4 REPLIGEN CORP For: May 13 Filed by: RYAN THOMAS F JR - StreetInsider.comForm 4 REPLIGEN CORP For: May 13 Filed by: RYAN THOMAS F JR - StreetInsider.com
streetinsider.com - May 17 at 11:21 PM
Form 4 REPLIGEN CORP For: May 13 Filed by: MUIR GLENN P - StreetInsider.comForm 4 REPLIGEN CORP For: May 13 Filed by: MUIR GLENN P - StreetInsider.com
streetinsider.com - May 17 at 11:21 PM
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate - NasdaqBristol Myers (BMY) Announces New Data on Cardiovascular Candidate - Nasdaq
nasdaq.com - May 17 at 6:21 PM
Moving Average Crossover Alert: Nokia (NOK) - NasdaqMoving Average Crossover Alert: Nokia (NOK) - Nasdaq
nasdaq.com - May 17 at 8:19 AM
Dillards (DDS) Surges 22.8%: Is This an Indication of Further Gains? - NasdaqDillard's (DDS) Surges 22.8%: Is This an Indication of Further Gains? - Nasdaq
nasdaq.com - May 17 at 8:19 AM
Repligen (RGEN) Enters Oversold Territory - Yahoo FinanceRepligen (RGEN) Enters Oversold Territory - Yahoo Finance
finance.yahoo.com - May 17 at 8:19 AM
Repligen (RGEN) Enters Oversold TerritoryRepligen (RGEN) Enters Oversold Territory
finance.yahoo.com - May 17 at 8:19 AM
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in FocusProthena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
finance.yahoo.com - May 12 at 7:38 PM
Analyst Forecasts For Repligen Corporation (NASDAQ:RGEN) Are Surging HigherAnalyst Forecasts For Repligen Corporation (NASDAQ:RGEN) Are Surging Higher
finance.yahoo.com - May 9 at 12:48 PM
Endos (ENDP) Earnings & Revenues Surpass Estimates in Q1 - NasdaqEndo's (ENDP) Earnings & Revenues Surpass Estimates in Q1 - Nasdaq
nasdaq.com - May 7 at 6:07 PM
5 of the Best Stocks to Buy Now for Striking Earnings Growth5 of the Best Stocks to Buy Now for Striking Earnings Growth
finance.yahoo.com - May 7 at 12:54 PM
Endos (ENDP) Earnings & Revenues Surpass Estimates in Q1Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
finance.yahoo.com - May 7 at 12:54 PM
Oversold Conditions For Repligen (RGEN) - NasdaqOversold Conditions For Repligen (RGEN) - Nasdaq
nasdaq.com - May 6 at 4:51 PM
Repligen Snagged By Broader Market; Shares Tumble Despite Beat And Raise - Investors Business DailyRepligen Snagged By Broader Market; Shares Tumble Despite Beat And Raise - Investor's Business Daily
investors.com - May 5 at 2:00 PM
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates - NasdaqRepligen (RGEN) Tops Q1 Earnings and Revenue Estimates - Nasdaq
nasdaq.com - May 5 at 1:26 AM
I Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease - NasdaqI Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease - Nasdaq
nasdaq.com - May 4 at 8:26 PM
Repligen Snagged By Broader Market; Shares Tumble Despite Beat And RaiseRepligen Snagged By Broader Market; Shares Tumble Despite Beat And Raise
finance.yahoo.com - May 4 at 8:26 PM
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View - Yahoo FinanceRepligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View - Yahoo Finance
finance.yahoo.com - May 4 at 3:25 PM
Repligen Corp (RGEN) Q1 2021 Earnings Call Transcript - Motley FoolRepligen Corp (RGEN) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 4 at 3:25 PM
Repligen Corp (RGEN) Q1 2021 Earnings Call TranscriptRepligen Corp (RGEN) Q1 2021 Earnings Call Transcript
fool.com - May 4 at 2:21 PM
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates - Yahoo FinanceRepligen (RGEN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 4 at 9:59 AM
This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.